0
TScan Therapeutics, Inc. Banner Image

TScan Therapeutics, Inc.

  • Ticker TCRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
TScan Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Waltham, Massachusetts
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneicMore hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
TScan Therapeutics, Inc.

Most Recent Annual Report

TScan Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

TScan Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!